Genzyme General News

Each company's shares sell for well more than 20 times this year's earnings estimate.

It's rare to find companies where extreme growth is complemented with trading multiples near its competitors.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

This morning, investment firm Collins Stewart downgraded shares of Genzyme from Buy to Hold as the viral re-contamination risk remains high.

Genzyme Corporation announced today that its genetic testing laboratory located in Phoenix, Arizona, has obtained the CAP 15189SM Accreditation to the International Standards Organization 15189:2007 Standard for laboratories from the College of American Pathologists.

Dec 8, 2009 - Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

Dec 7, 2009 - Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath in combination with Fludara to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to ...

Biotechnology company Celgene Corp. said Monday it will buy privately held Gloucester Pharmaceuticals Inc.

Thursday morning, Genzyme announced that it had met with the FDA regarding the regulatory path forward for approval of Pompe disease drug Lumizyme.

In a new Motley Fool series, we pit two stocks against each other on five criteria to determine the better buy.

One analyst said he was encouraged by Genzyme's new approach. Genzyme Corp. yesterday said it has scrapped its application to produce Lumizyme, a drug to treat the rare genetic disorder Pompe disease, in midsize bioreactors and instead will pursue a new pathway toward making the drug on a larger scale.

Hapoalim initiated coverage of the drug maker at Hold. Genzyme By Hapoalim Securities WE ARE INITIATING COVERAGE on Genzyme with a Hold rating and a 12-month target price of $55. Genzyme's franchise drug, Cerezyme , has been an unchallenged blockbuster for several years.

Genzyme Corp. has reopened enrollment in its Alglucosidase Alfa Temporary Access Program for adults suffering from Pompe disease to obtain access to the company's Lumizyme drug treatment prior to its approval for commercialization.

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program , a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme .

Henri Termeer, the CEO of Genzyme Corp. sold $10 million in shares at $50.47 on November 23.

Genzyme Ireland named LifeSciences Company of the Year Genzyme Ireland named LifeSciences Company of the Year at Export Industry Awards Genzyme Ireland, the biotechnology company that employs over 450 people in Waterford, has been named Life Sciences Company of the Year at the Irish Exporters Association's Export Industry Awards 2009.

Drug giant Pfizer Inc. , mounting a direct challenge to Cambridge biotech Genzyme Corp.

Cambridge-based Genzyme Corp. said it has begun shipping new vials of its Cerezyme drug manufactured at the Allston plant shut down earlier this year because of contamination.

Termeer's windfall occurred despite the following: It's not the first set of options that Termeer has cashed out.

Recently, we posted about misadventures of the leadership of biotechnology giant Genzyme.